Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | PTPRC | P08575 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19931854 | 1.00 | KMT2A (0.54) | KMT2AEPHX2PTPRCCASP3OPRD1 | |
| SCHEMBL26352259 | 0.95 | KMT2A (0.51) | KMT2AEPHX2PTPRCCASP3OPRD1 | |
| SCHEMBL27072523 | 0.95 | KMT2A (0.51) | KMT2AEPHX2PTPRCCASP3OPRD1 | |
| SCHEMBL30095461 | 0.91 | KMT2A (0.54) | KMT2AEPHX2PTPRCCASP3 | |
| SCHEMBL469368 | 0.91 | KMT2A (0.54) | KMT2AEPHX2PTPRCCASP3 | |
| Hydrochloric Acid SCHEMBL455447 | 0.90 | KMT2A (0.53) | KMT2AEPHX2PTPRCCASP3OPRD1 | |
| SCHEMBL18982241 | 0.90 | KMT2A (0.49) | KMT2AEPHX2CASP3 | |
| SCHEMBL18411293 | 0.89 | KMT2A (0.55) | KMT2AEPHX2PTPRCCASP3 | |
| SCHEMBL26172640 | 0.89 | KMT2A (0.60) | KMT2AEPHX2CASP3 | |
| SCHEMBL12391727 | 0.88 | KMT2A (0.57) | KMT2AEPHX2CASP3OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12122815-B2 | GIP receptor agonist peptide compounds and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-22 | — | — | US | disclosed |
| US-20220135638-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135638-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, VIPR1 | KMT2A 2759/4885EPHX2 4666/4885PTPRC 2023/4885 |
| US-12122815-B2 | GIP receptor agonist peptide compounds and uses thereof | GIPR, GLP1R, GPR119 | KMT2A 2421/4885EPHX2 4698/4885PTPRC 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.